ThromboGenics regains full rights to eye drug from Novartis

ThromboGenics has regained full global rights to Jetrea (ocriplasmin) from Alcon, a Novartis subsidiary.

The drug is approved to treat vitreomacular adhesion (VMA) in the US and vitreomacular traction (VMT) in Europe. Overall it is approved in 54 countries.

The companies say they will work together to ensure continuity and access to the drug for existing and future customers.

Under the terms of the agreement, ThromboGenics receives a cash amount of 53.7 million euros ($64 million) and a forthcoming equity investment of €10 million in ThromboGenics capital.